Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Theratechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Piramal Pharma Solutions Announces Sterile Fill\/Finish Program with Theratechnologies Inc. for TH1902 Peptide-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Epirium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Bolt Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Theratechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Piramal Pharma Solutions Announces Sterile Fill\/Finish Program with Theratechnologies Inc. for TH1902 Peptide-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Piramal Critical Care Launches First to Market Generic Zinc Sulfate Injection in the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Piramal Critical Care","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Piramal Critical Care Announces the U.S. Launch of Doxycycline for Injection, USP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Piramal Pharma Solutions

    Menu

    Piramal Pharma Solutions

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Piramal Critical Care

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Piramal Critical Care Announces the U.S. Launch of Doxycycline for Injection, USP

              Details:

              Doxycycline for Injection, USP is a Protein 30S ribosomal subunit inhibitor, which is used for prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

              Lead Product(s): Doxycycline

              Therapeutic Area: Infections and Infectious Diseases Product Name: Doxycycline-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Piramal Pharma Solutions

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials

              Details:

              Under the agreement, Piramal will produce additional cGMP liposome intermediate drug product to meet the increase in demand for its lead investigational targeted radiotherapeutic, rhenium (186Re) obisbemeda, for ongoing and planned clinical trials.

              Lead Product(s): Rhenium Obisbemeda

              Therapeutic Area: Oncology Product Name: 186RNL

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Plus Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Expanded Collaboration May 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Piramal Pharma Solutions

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Piramal Critical Care Launches First to Market Generic Zinc Sulfate Injection in the U.S.

              Details:

              Zinc Sulfate is a trace element indicated as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

              Lead Product(s): Zinc Sulphate

              Therapeutic Area: Neurology Product Name: Zinc Sulfate-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Piramal Pharma Solutions

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc.

              Details:

              The two Companies envision that the MSA will lead to clinical and commercial supply agreements for the drug product 186RNL (rhenium liposome) at the appropriate stage of development.

              Lead Product(s): Rhenium-186

              Therapeutic Area: Oncology Product Name: 186RNL

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Plus Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Piramal Pharma Solutions

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Piramal Pharma Solutions Announces Sterile Fill/Finish Program with Theratechnologies Inc. for TH1902 Peptide-Drug Conjugate

              Details:

              Piramal Pharma Solutions (PPS) is providing drug product formulation and manufacturing from the company’s Lexington, KY site in the U.S. Drug product material will be used in a first-in-humans clinical study for TH1902.

              Lead Product(s): Docetaxel-TH19P01 conjugate

              Therapeutic Area: Oncology Product Name: TH1902

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Theratechnologies

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Piramal Pharma Solutions

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Piramal Pharma Solutions Announces Sterile Fill/Finish Program with Theratechnologies Inc. for TH1902 Peptide-Drug Conjugate

              Details:

              The clinical material is produced at the Piramal Pharma manufacturing site, which is recognized globally for its expertise in sterile fill/finish services. It will be used in a Phase I trial for TH1902, Theratechnologies’ lead peptide-drug conjugate (docetaxel conjugate).

              Lead Product(s): TH1902

              Therapeutic Area: Oncology Product Name: TH1902

              Highest Development Status: Phase I Product Type: Peptide

              Recipient: Theratechnologies

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Piramal Pharma Solutions

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs

              Details:

              Epirium has advanced its first clinical candidate EPM-01 (Epicatechin) in Becker muscular dystrophy and plans to follow with drug development targeting other disorders associated with mitochondrial dysfunction and tissue degeneration.

              Lead Product(s): Epicatechin

              Therapeutic Area: Genetic Disease Product Name: EPM-01

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Epirium

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Piramal Pharma Solutions

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish

              Details:

              The Piramal Pharma Solutions team is applying its integrated drug development model to Bolt’s BDC-1001 for the treatment of patients with HER2-expressed solid tumors. The program encompasses formulation development and ISAC development and manufacture.

              Lead Product(s): BDC-1001,Nivolumab

              Therapeutic Area: Oncology Product Name: BDC-1001

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Recipient: Bolt Biotherapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY